Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 3—March 2017

pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia

Salim Allana, Elena Shashkina, Barun Mathema, Nino Bablishvili, Nestani Tukvadze, N. Sarita Shah, Russell R. Kempker, Henry M. Blumberg, Pravi Moodley, Koleka Mlisana, James C.M. Brust, and Neel R. GandhiComments to Author 
Author affiliations: Emory University Rollins School of Public Health and School of Medicine, Atlanta, Georgia, USA (S. Allana, R.R. Kempker, H.M. Blumberg, N.R. Gandhi); Rutgers University—Public Health Research Institute, Newark, New Jersey, USA (E. Shashkina); Columbia University Mailman School of Public Health, New York, New York, USA (B. Mathema); National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (N. Bablishvili, N. Tukvadze); Centers for Disease Control and Prevention, Atlanta (N.S. Shah); University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa (P. Moodley, K. Mlisana); Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA (J.C.M. Brust)

Main Article

Table 2

pncA gene sequencing results of 93 MDR TB and 10 XDR TB isolates from Georgia*

pncA mutation type†
Frequency (no. isolates)
Mutations specific to MDR TB isolates
1 CAG(Q) 141 CCG(P)‡ 20
2 CAT(H) 71 CGT(R)‡ 8
3 CAT(H) 71 CCT(P)‡ 6
4 Ins C after 420, 421ΔA,
CAG(Q) 141 CCG(P)‡ 3
5 TGG(W) 119 TTG(L)‡ 3
6 ATC(I) 6 CTC(L)§ 2
7 GAC(D) 49 GGC(G)‡ 2
8 CCA(P) 69 CGA(R)‡ 2
9 GTG(V) 155 GCG(A)§ 2
10 TTG(L) 4 TGG(W)‡ 1
11 ATC(I) 5 ACC(T)§ 1
12 CTG(L) 27 CCG(P)‡ 1
13 GAC(D) 49 GAG(E)‡ 1
14 CAC(H) 51 TAC(Y)‡ 1
15 CCG(P) 54 CAG(Q)‡ 1
16 GAC(D) 63 GCC(A)‡ 1
17 TCG(S) 66 CCG(P)‡ 1
18 CAT(H) 71 CCT(P);
Ins G after 547 (after G in GTT) 1
19 GGT(G) 97 AGT(S)‡ 1
20 TAC(Y) 103 TAA(Ter)‡ 1
21 TAC(Y) 103 TAG(Ter)‡ 1
22 GCC(A) 134 CCC(P) 1
23 ACG(T) 142 ATG(M)‡ 1
24 GGT(G) 162 TGT(C) 1
25 TGA(Ter) 187 CGA(R)§ 1
26 Del A at 298 1
27 Ins A after 389 (after T in GTG) 1
Ins G after 449 (after sec G in GGC)
Wild type

Mutations specific to XDR TB isolates
1 GTC(V) 7 GCC(A)‡ 2
2 ACC(T) 47 AGC(S)‡ 2
3 Ins TCT after 40 (after T In TGC) 1
4 GGC(G) 78 GAC(D)‡ 1
5 GGT(G) 97 CGT(R)‡ 1
6 TAC(Y) 103 GAC(D)‡ 1
7 GGC(G) 105 CGC(R) 1
Wild type 1

*del, deletion; ins, insertion; MDR, multidrug resistant; SNP, single-nucleotide polymorphism; TB, tuberculosis; XDR, extensively drug resistant. Row colors: pink, frameshift mutations: insertions or deletions; green, synonymous mutations or SNPs reported as being associated with phenotypic susceptibility to pyrazinamide; gray, SNPs reported as being associated with phenotypic resistance to pyrazinamide; blue, SNPs not previously reported in the literature.
†Insertion and deletions are presented with the nucleotide position where the polymorphism occurred; single nucleotide polymorphisms are presented with the codon position and the original and mutated three nucleotides and amino acid
‡Reported in the literature as being associated with resistance to pyrazinamide.
§Reported in the literature as being associated with susceptibility to pyrazinamide.

Main Article

Page created: February 17, 2017
Page updated: February 17, 2017
Page reviewed: February 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.